Development of pharmacodynamic biomarkers for ATR inhibitors

Molecular Oncology

Volumn 9, Issue 2, 2015, Pages 463-472

  Chen, Tao ^a,c   Middleton, Fiona K ^a   Falcon, Susanna ^b   Reaper, Philip M ^b   Pollard, John R ^b   Curtin, Nicola J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b VERTEX PHARMACEUTICALS   (United States)

^c MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

Author keywords

4NQO; ATR; Biomarker; PBMC; PChk1; UV; H2AX

Indexed keywords

ATR PROTEIN; BIOLOGICAL MARKER; CHECKPOINT KINASE 1; HISTONE H2AX; HYDROXYUREA; PROTEIN SERINE THREONINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; ATM PROTEIN; ATR PROTEIN, HUMAN; H2AFX PROTEIN, HUMAN; HISTONE; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; TUMOR MARKER; TUMOR PROTEIN;

ARTICLE; CANCER CELL LINE; CELL CYCLE PHASE; DNA DAMAGE; HUMAN; HUMAN CELL; IMMUNODETECTION; K562 CELL LINE; MCF 7 CELL LINE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; ULTRAVIOLET RADIATION; ANTAGONISTS AND INHIBITORS; FEMALE; GENETICS; MALE; METABOLISM;

ANTINEOPLASTIC AGENTS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; FEMALE; HISTONES; HUMANS; K562 CELLS; MALE; NEOPLASM PROTEINS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84921290284     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.09.012     Document Type: Article

References (33)

1. Chanoux R.A., Yin B., Urtishak K.A., Asare A., Bassing C.H., Brown E.J. ATR and H2AX cooperate in maintaining genome stability under replication stress. J.Biol. Chem. 2009, 284(9):5994-6003.
2. Chen T., Stephens P.A., Middleton F.K., Curtin N.J. Targeting the S and G2 checkpoint to treat cancer. Drug Discov. Today 2012, 17(5-6):194-202.
3. Cliby W.A., Lewis K.A., Lilly K.K., Kaufmann S.H. S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function. J.Biol. Chem. 2002, 277(2):1599-1606.
4. Cliby W.A., Roberts C.J., Cimprich K.A., Stringer C.M., Lamb J.R., Schreiber S.L., Friend S.H. Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints. EMBO J. 1998, 17(1):159-169.
5. Cooper S. Rethinking synchronization of mammalian cells for cell cycle analysis. Cell Mol. Life Sci. 2003, 60(6):1099-1106.
6. Ferguson H.A., Marietta P.M., Van Den Berg C.L. UV-induced apoptosis is mediated independent of caspase-9 in MCF-7 cells: a model for cytochrome c resistance. J.Biol. Chem. 2003, 278(46):45793-45800.
7. Fokas E., Prevo R., Hammond E.M., Brunner T.B., McKenna W.G., Muschel R.J. Targeting ATR in DNA damage response and cancer therapeutics. Cancer Treat. Rev. 2014, 40(1):109-117.
8. Fokas E., Prevo R., Pollard J.R., Reaper P.M., Charlton P.A., Cornelissen B., Vallis K.A., Hammond E.M., Olcina M.M., Gillies McKenna W., Muschel R.J., Brunner T.B. Targeting ATR invivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis. 2012, 3:e441.
9. Foote K.M., Blades K., Cronin A., Fillery S., Guichard S.S., Hassall L., Hickson I., Jacq X., Jewsbury P.J., McGuire T.M., Nissink J.W., Odedra R., Page K., Perkins P., Suleman A., Tam K., Thommes P., Broadhurst R., Wood C. Discovery of 4-{4-[(3R)-3-methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-y l}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy invivo antitumor activity. J.Med. Chem. 2013, 56(5):2125-2138.
10. Gagou M.E., Zuazua-Villar P., Meuth M. Enhanced H2AX phosphorylation, DNA replication fork arrest, and cell death in the absence of Chk1. Mol. Biol. Cell 2010, 21(5):739-752.
11. Huntoon C.J., Flatten K.S., Wahner Hendrickson A.E., Huehls A.M., Sutor S.L., Kaufmann S.H., Karnitz L.M. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. Cancer Res. 2013, 73(12):3683-3691.
12. Jacq X., Smith L., Brown E., Hughes A., Odedra R., Heathcote D., Barnes J., Powell S., Maguire S., Pearson V., Boros J., Caie P., Thommes P.A., Nissink W., Foote K., Jewsbury P.J., Guichard S.M. AACR 103rd Annual Meeting. Chicago, IL, Mar 31-Apr 4 2012.
13. Jones C.D., Blades K., Foote K., Guichard S.M., Jewsbury P.J., McGuire T.M., Nissink J.W., Odedra R., Tam K., Thommes P., Turner P., Wilkinson G., Wood C., Yates J.W. AACR Annual Meeting. Boston, MA, USA, April 15, 2013 2013.
14. Jones G.G., Reaper P.M., Pettitt A.R., Sherrington P.D. The ATR-p53 pathway is suppressed in noncycling normal and malignant lymphocytes. Oncogene 2004, 23(10):1911-1921.
15. Kawasumi M., Lemos B., Bradner J.E., Thibodeau R., Kim Y.S., Schmidt M., Higgins E., Koo S.W., Angle-Zahn A., Chen A., Levine D., Nguyen L., Heffernan T.P., Longo I., Mandinova A., Lu Y.P., Conney A.H., Nghiem P. Protection from UV-induced skin carcinogenesis by genetic inhibition of the ataxia telangiectasia and Rad3-related (ATR) kinase. Proc. Natl. Acad. Sci. U S A 2011, 108(33):13716-13721.
16. Massague J. G1 cell-cycle control and cancer. Nature 2004, 432(7015):298-306.
17. Matsumoto M., Yaginuma K., Igarashi A., Imura M., Hasegawa M., Iwabuchi K., Date T., Mori T., Ishizaki K., Yamashita K., Inobe M., Matsunaga T. Perturbed gap-filling synthesis in nucleotide excision repair causes histone H2AX phosphorylation in human quiescent cells. J.Cell Sci. 2007, 120(Pt 6):1104-1112.
18. Nghiem P., Park P.K., Kim Y., Vaziri C., Schreiber S.L. ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation. Proc. Natl. Acad. Sci. U S A 2001, 98(16):9092-9097.
19. Nishida H., Tatewaki N., Nakajima Y., Magara T., Ko K.M., Hamamori Y., Konishi T. Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response. Nucleic Acids Res. 2009, 37(17):5678-5689.
20. Peasland A., Wang L.Z., Rowling E., Kyle S., Chen T., Hopkins A., Cliby W.A., Sarkaria J., Beale G., Edmondson R.J., Curtin N.J. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. Br. J. Cancer 2011, 105(3):372-381.
21. Pires I.M., Olcina M.M., Anbalagan S., Pollard J.R., Reaper P.M., Charlton P.A., McKenna W.G., Hammond E.M. Targeting radiation-resistant hypoxic tumour cells through ATR inhibition. Br. J. Cancer 2012, 107:291-299.
22. Prevo R., Fokas E., Reaper P.M., Charlton P.A., Pollard J.R., McKenna W.G., Muschel R.J., Brunner T.B. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Cancer Biol. Ther. 2012, 13(11).
23. Reaper P.M., Griffiths M.R., Long J.M., Charrier J.D., MacCormick S., Charlton P.A., Golec J.M.C., Pollard J.R. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat. Chem. Biol. 2011, 7:428-430.
24. Redon C.E., Nakamura A.J., Zhang Y.W., Ji J.J., Bonner W.M., Kinders R.J., Parchment R.E., Doroshow J.H., Pommier Y. Histone {gamma}H2AX and Poly(ADP-Ribose) as clinical pharmacodynamic biomarkers. Clin. Cancer Res. 2010, 16(18):4532-4542.
25. Smith J., Tho L.M., Xu N., Gillespie D.A. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv. Cancer Res. 2010, 108:73-112.
26. Stiff T., Cerosaletti K., Concannon P., O'Driscoll M., Jeggo P.A. Replication independent ATR signalling leads to G2/M arrest requiring Nbs1, 53BP1 and MDC1. Hum. Mol. Genet. 2008, 17(20):3247-3253.
27. Sultana R., Abdel-Fatah T., Perry C., Moseley P., Albarakti N., Mohan V., Seedhouse C., Chan S., Madhusudan S. Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells. PLoS One 2013, 8(2):e57098.
28. Toledo L.I., Altmeyer M., Rask M.B., Lukas C., Larsen D.H., Povlsen L.K., Bekker-Jensen S., Mailand N., Bartek J., Lukas J. ATR prohibits replication catastrophe by preventing global exhaustion of RPA. Cell 2013, 155(5):1088-1103.
29. Toledo L.I., Murga M., Zur R., Soria R., Rodriguez A., Martinez S., Oyarzabal J., Pastor J., Bischoff J.R., Fernandez-Capetillo O. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat. Struct. Mol. Biol. 2011, 18(6):721-727.
30. Vrouwe M.G., Pines A., Overmeer R.M., Hanada K., Mullenders L.H. UV-induced photolesions elicit ATR-kinase-dependent signaling in non-cycling cells through nucleotide excision repair-dependent and -independent pathways. J.Cell Sci. 2011, 124(Pt 3):435-446.
31. Ward I.M., Chen J. Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress. J.Biol. Chem. 2001, 276(51):47759-47762.
32. Ward I.M., Minn K., Jorda K.G., Chen J. Accumulation of checkpoint protein 53BP1 at DNA breaks involves its binding to phosphorylated histone H2AX. J.Biol. Chem. 2003, 278(22):19579-19582.
33. Zhao H., Piwnica-Worms H. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol. Cell Biol. 2001, 21(13):4129-4139.